•  

News - TIAP

FedDev Ontario Funding Support – Portfolio Investments

On October 9, 2020, the Honourable Mélanie Joly, Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR  Under this Agreement, TIAP has to date made the following investments in our portfolio startup companies: Bitnobi - $15,000, April 1, 2019 Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020 Elarex (McMaster University) - $50,000, ... Read more

Phenotips Raises $2.5M in First Round of Financing

Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this round, participated with additional $100K through its FedDev program. This brings TIAP's total investment as of September 2021 to $300K. Read more about the financing round here. Phenotips has developed the world’s first "Genomic Health Record,” which offers software to standardize and share genomic medicine workflows. It is now translated into 5 ... Read more

Roadmap for an Integrated Life Sciences Ecosystem In Ontario

LSO - Life Sciences Ontario - prepared an in-depth and informative report on the importance of the life science sector in Ontario. TIAP was one of the endorsing organizations. The report was published in May 2021. https://lifesciencesontario.ca/wp-content/uploads/2021/05/LSO-RoadMap-Final.pdf   Read more

7D Surgical Acquired By Seaspine

7D Surgical was acquired by SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders. The agreement is a cash and stock deal valued at $110 million, subject to customary adjustments. bit.ly/3dfF3wGbit.ly/3dfF3wG Read more

Miroculus Funding News

In February 2021, Miroculus closed a Series B financing extension bringing the total capital raised in the round to $45 million. bwnews.pr/3s9abDsbwnews.pr/3s9abDs     Read more

Notch Therapeutics Raises $85M Series A Financing

TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges ... Read more

Webinar February 24, 2021: Adventures in Drug Hunting – Identify and Advance Your Drug-Like Molecule

On February 24, 2021 TIAP hosted a LAB150 webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule.  Here is the full description of the webinar content: In the second of three webinars in the LAB150 series, we turn to the initial stages of identifying and developing a therapeutic compound. This follows our previous discussion of target identification and validation. Now that you have a validated therapeutic target, how do you go about discovering modulators of this target in an efficient and rational ... Read more

TIAP & Amgen Co-funds transformative projects to support new venture development

December 8, 2020 TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids). The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ... Read more

Webinar: Staying on Target – How to Determine if Your Research Program is Ready for Drug Delivery

Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development November 17, 2020 - 12-1:30 PM ET Click here to hear a recording of the webinar: http://bit.ly/2O5dDR4  In the first of three webinars in the LAB150 series on drug discovery and development, we focus on the initial steps on the long path of bringing a new drug to market and to patients in need. Specifically, we examine approaches to target ... Read more

Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes

November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations,  announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). Red more here: https://bit.ly/34QRAn6 Read more
Page 1 of 3912345...102030...Last »